Quantel Medical announced the launch of the SubCyclo laser procedure at the World Glaucoma Congress meeting in Helsinki, Finland. SubCyclo is a novel non-thermal glaucoma treatment based on the transscleral cyclophotocoagulation principle. The procedure lowers IOP by stimulating the ciliary body and the uveoscleral pathway, a route of aqueous outflow, without destructive effects. The SubCyclo probe is available on Quantel’s Supra 810 laser and based on SubLiminal proprietary technology.
"It’s a non-thermal cyclophotocoagulation procedure, and it’s a non-destructive laser procedure which has an action on the ciliary body to decrease the aqueous humor production," Jan-Philippe Heydel, marketing director at Quantel Medical, said in an interview with Eyewiretoday.com. "It's also used to increase the aqueous outflow by increasing the pathway of the uveoscleral pathway. Again, it's non-destructive so it’s a repeatable treatment and it’s a laser procedure that is not limited to refractory glaucoma."
“We are delighted to bring this breakthrough, non-destructive treatment to millions of glaucoma sufferers,” Jean?Marc Gendre, CEO of Quantel Medical, said in the news release. “The ability to lower IOP safely, with the added advantages of speed and ease for patients and surgeons alike, makes this a very exciting advance in treatment of glaucoma.”
Additional information on the SubCyclo procedure with 810nm Subliminal technology will be available during WGC 2017 in exhibit booth #1004.